{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:21:49Z","timestamp":1792408909815,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100418","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T22:32:57Z","timestamp":1645828377000},"page":"100418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study"],"prefix":"10.1016","volume":"7","author":[{"given":"N.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Galland-Girodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Avrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bouledrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coudurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Egenod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Odier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tillon-Strozyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2022.100418_bib1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2022.100418_bib2","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1158\/1078-0432.CCR-12-0550","article-title":"Identifying and targeting ROS1 gene fusions in non-small cell lung cancer","volume":"18","author":"Davies","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100418_bib3","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100418_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100418_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100418_bib6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100418_bib7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial","volume":"14","author":"Michels","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100418_bib8","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100418_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2022.100418_bib10","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer","volume":"2017","author":"Gainor","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2022.100418_bib11","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100418_bib12","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100418_bib13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100418_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jtho.2020.04.019","article-title":"An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor-refractory ALK-positive or ROS1-positive NSCLC","volume":"15","author":"Zhu","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100418_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100418_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/ph13110371","article-title":"Later-line treatment with lorlatinib in ALK- and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis","volume":"13","author":"Hochmair","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100418_bib17","doi-asserted-by":"crossref","first-page":"omy009","DOI":"10.1093\/omcr\/omy009","article-title":"Progressive renal insufficiency related to ALK inhibitor, alectinib","volume":"2018","author":"Nagai","year":"2018","journal-title":"Oxf Med Case Reports"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100418_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.esmoop.2022.100418_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2018.06.017","article-title":"Effects of crizotinib on creatinine clearance and renal hemodynamics","volume":"122","author":"Meijer-Schaap","year":"2018","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100418_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1078155220961549","article-title":"Lorlatinib induced proteinuria: a case report","volume":"27","author":"Lee","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"21","key":"10.1016\/j.esmoop.2022.100418_bib21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100418_bib22","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort","volume":"33","author":"Mazi\u00e8res","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100418_bib23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice","volume":"13","author":"Park","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100418_bib24","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:58Z","timestamp":1761855958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000394"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100418","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100418"}}